PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17662692-3	2007	We provide evidence that the proteasome-inhibitors Bortezomib and MLN273 are both substrates of MDR-1 by using knockdown of MDR-1 via a transposon-based vector system stably expressing siRNA against MDR-1 in MDR-1-overexpressing K562/Dox cells.	Bortezomib	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	96-101	
17662692-3	2007	We provide evidence that the proteasome-inhibitors Bortezomib and MLN273 are both substrates of MDR-1 by using knockdown of MDR-1 via a transposon-based vector system stably expressing siRNA against MDR-1 in MDR-1-overexpressing K562/Dox cells.	Bortezomib	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	124-129	
17662692-3	2007	We provide evidence that the proteasome-inhibitors Bortezomib and MLN273 are both substrates of MDR-1 by using knockdown of MDR-1 via a transposon-based vector system stably expressing siRNA against MDR-1 in MDR-1-overexpressing K562/Dox cells.	Bortezomib	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	124-129	
17662692-3	2007	We provide evidence that the proteasome-inhibitors Bortezomib and MLN273 are both substrates of MDR-1 by using knockdown of MDR-1 via a transposon-based vector system stably expressing siRNA against MDR-1 in MDR-1-overexpressing K562/Dox cells.	Bortezomib	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	124-129	
17662692-7	2007	Our report provides evidence that MLN273 and, to a lesser degree, Bortezomib are both MDR-1-substrates, which might be relevant for drug-resistance in cancer.	Bortezomib	66-76	ATP binding cassette subfamily B member 1	Homo sapiens	86-91